Anne Marie Quinn
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$4.1MFederal grants as PI11 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
11 awards · $4.1M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| May 23, 2023 | NIH | SBIR Phase II Live Cell Fluorescent Assays for SARS-CoV-2 protease activity and COVID-19 Drug Discovery | $300K | MONTANA MOLECULAR, LLC |
| May 13, 2022 | NIH | SBIR Phase II Live Cell Fluorescent Assays for SARS-CoV-2 protease activity and COVID-19 Drug Discovery | $300K | MONTANA MOLECULAR, LLC |
| Jan 28, 2022 | NIH | SBIR Phase II An optimized screening platform for identifying and quantifying biased agonists as drugs for the treatment of Opioid Use Disorder | $315K | MONTANA MOLECULAR, LLC |
| Jan 26, 2021 | NIH | SBIR Phase II An optimized screening platform for identifying and quantifying biased agonists as drugs for the treatment of Opioid Use Disorder | $482K | MONTANA MOLECULAR, LLC |
| Jun 24, 2020 | NIH | SBIR Phase II A robust assay for detecting agonist bias in living cells. | $600K | MONTANA MOLECULAR, LLC |
| Sep 16, 2019 | NIH | SBIR Phase II An optimized screening platform for identifying and quantifying biased agonists as drugs for the treatment of Opioid Use Disorder | $221K | MONTANA MOLECULAR, LLC |
| Jun 25, 2019 | NIH | SBIR Phase II A robust assay for detecting agonist bias in living cells. | $635K | MONTANA MOLECULAR, LLC |
| Aug 13, 2018 | NIH | SBIR Phase II Development of technologies to advance fast and accurate tools for measuring fluorescence in living cells, with emphasis on developing assays optimized for screening in neuronal cells and brain tissue | $210K | MONTANA MOLECULAR, LLC |
| Sep 14, 2017 | NIH | SBIR Phase II Development of technologies to advance fast and accurate tools for measuring fluorescence in living cells, with emphasis on developing assays optimized for screening in neuronal cells and brain tissue | $227K | MONTANA MOLECULAR, LLC |
| Aug 15, 2017 | NIH | SBIR Phase I A robust assay for detecting agonist bias in living cells. | $193K | MONTANA MOLECULAR, LLC |
| Apr 16, 2015 | NIH | SBIR Phase II Fast and Accurate Tools for Measuring Fluorescence in Living Cells | $582K | MONTANA MOLECULAR, LLC |
Peer ranks
Federal funding#380
Awards as PI#106
Patents#273
Companies
- MONTANA MOLECULAR, LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.